Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Expert Guidance on Novel Approaches in the Management of Myelofibrosis

Premiere Date: Wednesday, January 11, 2023

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. PA (aapa)
6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Thursday, January 11, 2024
Note: Credit Is No Longer Available

Faculty

Ruben A. Mesa, MD, FACP (Moderator) Executive Director, Mays Cancer Center at UT Health San Antonio MD Anderson Mays Family Foundation Distinguished University Presidential Chair Professor of Medicine UT Health San Antonio San Antonio, TX

Angela G. Fleischman, MD, PhD  Associate Professor Division of Hematology/Oncology University of California, Irvine Irvine, CA

Aaron T. Gerds, MD, MS  Associate Professor of Medicine, Hematology & Medical Oncology Deputy Director for Clinical Research Cleveland Clinic Taussig Cancer Institute Medical Director, Case Comprehensive Cancer Center Clinical Research Office Principal Investigator, Case Lead Academic Participating Site Cleveland, OH

Statement of Need

Myelofibrosis (MF) is a rare bone marrow cancer characterized by severe anemia, weakness, fatigue, and other constitutional symptoms that can severely compromise quality of life (QoL). JAK/STAT pathway inhibition is the standard of care for patients with symptomatic MF. However, certain JAK inhibitors (JAKi) can exacerbate anemia and may be unsuitable for patients dependent on red blood cell (RBC) transfusions.

Other key signaling pathways are being explored to foster development of novel therapies that can overcome challenges associated with JAKis, but clinicians need guidance on these novel therapies in order to optimize clinical outcomes. This educational initiative will survey the expanding treatment options for patients with MF, including non-JAKi agents targeting non-canonical molecular pathways.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Identify molecular and clinical features of MF that inform care plans.
• Evaluate novel and investigational therapies for the management of MF.
• Devise personalized strategies to integrate emerging evidence for MF.

Financial Support

This educational activity is supported by an educational grant from GSK.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in hematology or oncology.

Credit Information

ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning formats:
Enduring material

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Mesa reports the following financial relationships:

Consultant: AbbVie Inc.; Blueprint Medicines Corporation; Bristol Myers Squibb; CTI Biopharma Corp.; Genentech, Inc.; Geron; GSK; Incyte; Novartis Pharmaceuticals Corporation; Sierra Oncology, Inc.; and Telios pharmaceuticals

Editorial Advisory Board: Clinical Advances in Hematology & Oncology

Grants: Mays Cancer Center P30 Cancer Center Support Grant from National Cancer Institute (CA054174)

Research Support: AbbVie Inc.; Blueprint; Bristol Myers Squibb; CTI Biopharma Corp.; Genentech, Inc.; Incyte; MorphoSys; and Sierra Oncology, Inc.

The following CME Outfitters peer reviewer and staff have no financial relationships:

Dr. Fleischman reports the following financial relationships:

Advisory Board: Incyte; PharmaEssentia Corporation; and Sierra Pharma

Speakers Bureau: CTI Biopharma Corp. and PharmaEssentia Corporation

Dr. Gerds reports the following financial relationships:

Advisory Board: AbbVie Inc.; CTI Biopharma Corp.; MorphoSys; PharmaEssentia Corporation; and Sierra Oncology, Inc./GSK

Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)

Thomas Mitchell (planning committee)

David Modrak, PhD (planning committee)

Susan H. Yarbrough, CHCP (planning committee)

Sandra Caballero, PharmD (planning committee)

Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).